Last reviewed · How we verify
Higher doses of vasopressor therapy for a MAP of 75 mmHg
Higher doses of vasopressor therapy for a MAP of 75 mmHg is a Small molecule drug developed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. It is currently FDA-approved.
At a glance
| Generic name | Higher doses of vasopressor therapy for a MAP of 75 mmHg |
|---|---|
| Sponsor | Centre de recherche du Centre hospitalier universitaire de Sherbrooke |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher doses of vasopressor therapy for a MAP of 75 mmHg CI brief — competitive landscape report
- Higher doses of vasopressor therapy for a MAP of 75 mmHg updates RSS · CI watch RSS
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke portfolio CI
Frequently asked questions about Higher doses of vasopressor therapy for a MAP of 75 mmHg
What is Higher doses of vasopressor therapy for a MAP of 75 mmHg?
Higher doses of vasopressor therapy for a MAP of 75 mmHg is a Small molecule drug developed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke.
Who makes Higher doses of vasopressor therapy for a MAP of 75 mmHg?
Higher doses of vasopressor therapy for a MAP of 75 mmHg is developed and marketed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke (see full Centre de recherche du Centre hospitalier universitaire de Sherbrooke pipeline at /company/centre-de-recherche-du-centre-hospitalier-universitaire-de-sherbrooke).
What development phase is Higher doses of vasopressor therapy for a MAP of 75 mmHg in?
Higher doses of vasopressor therapy for a MAP of 75 mmHg is FDA-approved (marketed).